Imagion Biosystems announced on ASX that it has received a total of $40,000 for the exercise of 800,000 Listed Options exercisable at 5 cents, expiring on 26 November 2021.
Please click to review the full announcement at ASX.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer